1. Myasthenia Gravis Victor Politi,M.D.
Medical Director, SVCMC School of Allied Health, Physician Assistant Program

2. Pathophysiology
The underlying defect is a decrease in the number of available Ach receptors at neuromuscular junctions due to an antibody mediated autoimmune attack

3. Pathophysiology Pathophysiology
ACh synthesized in the motor nerve terminal and stored in vesicles
ACh released causes miniature end plate potentials
Action potential release ACh and combined with postsynaptic receptors
Postsynaptic channels are open allowing entry of sodium producing depolarization of muscle fiber

4. Pathophysiology A process is terminated by hydrolysis of ACh by AChE
The fundamental defect is a decrease in the number of ACh receptors at the postsynaptic muscle membrane, therefore, although ACh is released normally it produces small end plate potentials which fail to trigger muscle action potentials

5. MG- Autoantibodies protect against the postsynaptic acetylcholine receptors

6. Pathophysiology
The neuromuscular abnormalities caused by an autoimmune response mediated by specific anti AChR antibodies
These antibodies reduce the available AChR’s at neuromuscular junctions

8. Myasthenia gravis (MG)
Neuromuscular disorder characterized by weakness and fatigability of skeletal muscles
There is no cure for MG but treatment is highly effective

9. Pathology
The neuromuscular abnormalities in MG are brought about by an autoimmune response mediated by specific anti-AChR antibodies
the thymus is abnormal in approximately 75% of patients with MG
In 65% of patients the thymus is hyperplastic

10. Clinical Features Prevalence rate 1 in 10,000 people
Can affect any age group
women - peak incidence 20’s-30’s
men - peak incidence 50’s-60’s
Women affected more than men
Cardinal features - weakness and fatigability

11. Clinical Features
Weakness typically increases during repeated use (fatigue) and may improve during rest or sleep
Course of MG - variable
Remissions - rarely complete or permanent

12. Clinical Features
Unrelated infections or systemic disorders may lead to increased myasthenic weakness and may precipitate a “crisis”
A crisis is if weakness in respiration or swallowing becomes severe and respiratory assistance or intubation is necessary

13. Clinical Features Characteristic pattern of muscle weakness
early involvement -lids and extraocular muscles
diplopia and ptosis common initial complaints
Difficulty in swallowing may occur

15. Clinical Features
In 85% of cases, weakness becomes generalized, affecting limb muscles as well
Limb weakness is often proximal and may be asymmetric
deep tendon reflexes are preserved

17. Diagnosis and Evaluation
Suspect on basis of weakness and fatigability as previously described
No loss of reflexes or impairment of sensation or other neurologic function
Edrophonium- initial dose 2mg IV, second dose 8mg IV
ACh receptor antibody detectable in 80% of all myosthenic patients

18. Differential Diagnosis
Several other conditions that cause weakness or the cranial and/or somatic musculature must be considered in the differential diagnosis of MG:
drug induced myasthenia, Lambert-Eaton myasthenic syndrome,neurasthenia
hyperthyroidism, botulism, intracranial mass lesions and progressive external ophthalmoplegia

19. Differential Diagnosis
Drugs that may exacerbate MG
penicillamine
aminoglycoside antibiotics
procainamide

20. Lambert-Eaton myasthenic syndrome
Presynaptic disorder of neuromuscular junction - causes muscle weakness similar to MG
proximal muscles of lower limbs most commonly affected
ptosis of the eyelids and diplopia in up to 70% of patients

21. LES- Autoantibodies against the presynaptic voltage-gated calcium channels

22. Lambert-Eaton myasthenic syndrome
MG and Lambert-Eaton myasthenic syndrome are readily distinguished
patients with Lambert-Eaton syndrome have depressed or absent reflexes, autonomic changes (dry mouth, impotence) and show incremental responses on repetitive nerve stimulation

23. Lambert-Eaton myasthenic syndrome
LES is caused by auto antibody directed against calcium channels on the motor nerve terminals resulting in impaired release of ACh

24. Lambert-Eaton myasthenic syndrome
Majority of patients with this syndrome have an associated malignancy - most commonly small cell carcinoma of the lung
The diagnosis of Lambert-Eaton may signal the presence of the tumor long before it would otherwise be detected

25. Lambert-Eaton myasthenic syndrome
Treatment involves plasmapheresis and immunosuppression, as for MG

26. Myasthenic patients have an increased incidence of several associated disorders
Thymic abnormalities - 75% of cases
thymoma
Hyperthyroidism - 3-8% of cases
may worsen the myasthenic weakness
other autoimmune disorders
blood tests for rheumatoid factor, antinuclear antibodies

27. Thymoma on CT of chest

28. Chronic infection of any kind can exacerbate MG
measurements of ventilatory function are valuable because of the frequency and seriousness of respiratory impairment in myasthenic patients

29. Because of the side effects of glucocorticoids and other immunosuppressive agents used in the treatment of MG, a through medical history/exam should be made
Particular attention should be paid to evidence of chronic or latent infection (tuberculosis/hepatitis), HTN, diabetes, renal impairment, and glaucoma

30. Therapy
The prognosis has improved greatly for MG cases due to advances in treatment
virtually all MG patients can be returned to productive lives with proper therapy

31. Therapy Anticholinesterase medications immunosuppressive agents
pyridostigmine
immunosuppressive agents
glucocorticoids, azathiopriane
thymectomy
plasmapheresis

32. Management of myasthenic crisis
Exacerbation of weakness sufficient to endanger life
respiratory failure
aspiration
The possibility that the deterioration should be due to excessive anti -ChE medication (cholinergic crisis) is best excluded by temporarily stopping anti-ChE drugs

33. Management of myasthenic crisis
The most common cause of crisis is intercurrent infection
The myasthenic patient with fever and early infection should be treated like other immunocompromised patients with early antibiotic therapy, respiratory assistance, and pulmonary physiotherapy. Plasmapheresis is frequently helpful in hastening recovery

34. Questions ??